Collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements, industry’s first In Stock GMP-compliant Cryopreserved Leukopaks significantly decrease lead time
SaniSure, a global developer and manufacturer of single-use technology for the biopharmaceutical industry, announced today it has acquired GL Engineering (GLE) of East Hanover, New Jersey.
Cytiva’s FlexFactory is a one-stop solution for equipment and services following single-use technology and a modular design tailored to the manufacturer’s needs.
Altasciences today announced the continued expansion of their formulation, manufacturing, and analytical services facilities in Philadelphia, PA.
Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines.
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located in Providence Park at 2501 Earl Rudder Freeway in College Station.
The scientists envision that such transient engineered technologies one day could complement or replace pharmaceutical treatments for a variety of medical conditions in humans. This type of technology, which the researchers refer to as a “bioresorbable electronic medicine,” provides therapy and treatment over a clinically relevant period of time and directly at the site where it’s needed, thereby reducing side effects or risks associated with conventional, permanent implants.
Feinstein Institute researchers publish analysis about link between neuroscience and immunity. A detailed account of how the central and peripheral nervous systems signal the immune system could lead to new therapies — including those in the new field of bioelectronic medicine.
Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands to accommodate the increasing market demand.
